Urolithin A and Ribosomes

Ribosomes make proteins. Techinno Health studied whether MitoIgnite® urolithin A affects new protein synthesis in stressed cells: in cell models including cardiac and liver cells, stress lowered the new-protein signal to about 20–35% of control, and 5 µM MitoIgnite® raised it about two- to three-fold. These are company-reported cell-culture results, not a human or clinical effect.

MitoIgnite® cell-model study

Reported 26 October 2026 · company-reported experiments
Cell modelsincl. AC16 · AML12
Stress modelsoxidative · cell-cycle arrest · glycation
ReadoutHPG-labelled new protein
After stress≈ 20–35% of control
With 5 µM MitoIgnite®≈ 2–3× vs stressed
PatentPCT application filed Oct 2026
MitoIgnite® HPG-labelled new protein synthesis in AC16 and AML12 cells
HPG-labelled new proteins (green) and nuclei (blue). A–B AC16 cells, C–D AML12 cells. Source: Techinno Health company-reported cell experiments.

What the data show, and what they do not

  • The figure measures new protein synthesis. On its own it does not establish which upstream mechanism caused the change, or demonstrate a health benefit in humans.
  • 5 µM is a cell-culture concentration and a laboratory readout, not an oral dose or a clinical effect size.
  • Ribosome biogenesis, a change in ribosome-related gene expression, and a measured change in new protein synthesis are related observations, but they are not interchangeable results.

Patent status

PCT international patent application filed (October 2026) for a new urolithin A pathway mechanism: ribosome biogenesis and nascent protein synthesis. An application is not a granted patent. On this basis Techinno Health is China’s first urolithin A ingredient supplier with its own, self-researched efficacy patent. This refers to a PCT international patent application on a mechanism of urolithin A itself (October 2026), based on public patent records as of 12 November 2026.

How to cite this research

Techinno Health. Urolithin A and ribosomes: MitoIgnite® cell-model data (HPG-labelled new protein synthesis). Company-reported experiments, reported 26 October 2026. https://techinnohealth.com/en/ua/ribosome/Reported in a NutraIngredients paid partner feature by Techinno Health (26 October 2026); not an independent peer-reviewed publication. Read the NutraIngredients partner feature

Questions about urolithin A and ribosomes

Does urolithin A affect ribosomes?
The research question is whether urolithin A influences ribosome production and the synthesis of new proteins. Techinno Health’s MitoIgnite® data come from cell models; they do not establish a ribosome-mediated clinical benefit.
What did Techinno Health measure?
Cell models including AC16 cardiac and AML12 liver cells were exposed to oxidative stress, cell-cycle arrest or glycation-related stress, and HPG labelling measured newly made proteins. Stressed cells produced about 20–35% of the control signal; 5 µM MitoIgnite® urolithin A increased it about two- to three-fold relative to the stressed condition.
Is the ribosome mechanism patented?
A PCT international patent application for a new urolithin A pathway mechanism (ribosome biogenesis and nascent protein synthesis) was filed in October 2026. An application is not a granted patent.
How can I get the research information or a sample?
Contact Techinno Health with your intended application, target market, grade and requested quantity. We can discuss MitoIgnite® specifications, COAs, samples and research collaboration.

Request the product brochure · book a call

ty-sales@taiyi-nb.com